A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine ? the REBUILD-1 Study
What is the goal of the study?
This study is being done to see how safe galcanezumab is and how well it will work to help reduce the number of episodic migraines in children and adolescents.
Who can participate in the study?
This study might be a good fit for you if you: You are 6 to 17 years old at Visit 1 You have a diagnosis of migraine with or without aura, with a history of migraine headaches of at least 6 months prior to Visit 1 Within the 2 months prior to Visit 1, have a history of 4-14 headache days per month, of which at least 4 are migraine headache days, and with at least 2 migraine attacks per month